Posted by Michael Wonder on 20 Dec 2024
Tryngolza (olezarsen) approved in US as first ever treatment for adults living with familial chylomicronemia syndrome as an adjunct to diet
19 December 2024 - Tryngolza shown to significantly reduce triglycerides and substantially reduce acute pancreatitis events in adults with familial chylomicronaemia syndrome; a rare, highly debilitating and life-threatening disease.
Ionis Pharmaceuticals announced today that the US FDA has approved Tryngolza (olezarsen) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronaemia syndrome, a rare, genetic form of severe hypertriglyceridaemia that can lead to potentially life-threatening acute pancreatitis.
